» Articles » PMID: 32823901

Understanding COVID-19: From Origin to Potential Therapeutics

Overview
Publisher MDPI
Date 2020 Aug 23
PMID 32823901
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, a global pandemic era of public health concerns is going on with the Coronavirus Disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was reported from Wuhan's Huanan seafood market in China late December 2019. Bats, pangolins, and snakes have been nominated as salient carriers of the virus. Thanks to its high pathogenicity, it can cause severe respiratory infections. Fever, dry cough, sore throat, pneumonia, septic shock, and ground-glass opacities are the foremost clinical manifestations of COVID-19. Immunocompromised patients are at high risk for COVID-19 infection and may lead to death. Scientist and government agencies around the globe are putting forward their best efforts and resources for the effective treatment of human coronavirus infections; however, neither vaccines nor antiviral drugs are available for the treatment of human coronaviruses (HCoV) infections such as SARS (severe acute respiratory syndrome), MERS (Middle Eastern respiratory syndrome), and COVID-19. Since the outbreak, a plethora of research and review articles have been published. Moreover, the mass media has bombarded the public with conflicting opinions about the pandemic. There is a dire need for accurate and reliable information concerning this pandemic. In this review, we have compiled the up to date information about the origins, evolution, epidemiology, and pathogenesis of this disease. Moreover, very few reports have addressed the clinical features and current status of treatment for COVID-19; we have adequately addressed these topics in detail in this review. Finally, a detailed account of clinical trials of vaccines and other therapeutics currently in progress has been delineated.

Citing Articles

Long COVID: a cross-sectional study of respiratory muscle strength, lung function, and persistent symptoms at one year after hospital discharge.

Reboucas E, Ramos T, Sousa B, Costa R, Gouveia S, Silva I J Bras Pneumol. 2024; 50(5):e20240246.

PMID: 39661840 PMC: 11601093. DOI: 10.36416/1806-3756/e20240246.


In-silico approach to designing effective antiviral drugs against SARS-CoV-2 and SARS-CoV-1 from reported phytochemicals: a quality improvement study.

Tuz-Zohura F, Shawon A, Hasan M, Aeyas A, Chowdhury F, Khandaker M Ann Med Surg (Lond). 2023; 85(7):3446-3460.

PMID: 37427236 PMC: 10328662. DOI: 10.1097/MS9.0000000000000839.


Clinical Features and Treatment Outcomes of COVID-19 Admissions in the Can Tho City Hospital of Tuberculosis and Respiratory Diseases, Vietnam: A Hospital-Based Observational Study.

Do Tran H, Hung T, Thuy Phuong T, Tam L, Gia Tran H, Le P Healthcare (Basel). 2023; 11(11).

PMID: 37297772 PMC: 10252595. DOI: 10.3390/healthcare11111632.


Socioeconomic disparities associated with mortality in patients hospitalized for COVID-19 in Colombia.

Mendoza Cardozo O, Perez Bedoya J, Ruiz Galvis L, Perez Aguirre C, Rodriguez Rey B, Barengo N Front Public Health. 2023; 11:1139379.

PMID: 37151581 PMC: 10157783. DOI: 10.3389/fpubh.2023.1139379.


Exploring Radiologists' Burnout in the COVID-19 Era: A Narrative Review.

Gabelloni M, Faggioni L, Fusco R, De Muzio F, Danti G, Grassi F Int J Environ Res Public Health. 2023; 20(4).

PMID: 36834044 PMC: 9966123. DOI: 10.3390/ijerph20043350.


References
1.
Peng F, Tu L, Yang Y, Hu P, Wang R, Hu Q . Management and Treatment of COVID-19: The Chinese Experience. Can J Cardiol. 2020; 36(6):915-930. PMC: 7162773. DOI: 10.1016/j.cjca.2020.04.010. View

2.
Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-147. PMC: 7146714. DOI: 10.1016/j.thromres.2020.04.013. View

3.
Qu R, Ling Y, Zhang Y, Wei L, Chen X, Li X . Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020; 92(9):1533-1541. PMC: 7228291. DOI: 10.1002/jmv.25767. View

4.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

5.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View